About Concordia International
Concordia International is a Healthcare company based in Oakville (Canada) founded in 2016 by Mark Thompson. Distributes specialty pharmaceutical drugs to healthcare providers. It operates on a B2B model. The company has 264 employees. Concordia International has completed 1 acquisition, including Amdipharm Mercury. Its chief executive, as recorded, is Mark Thompson. Its Indian entity Advanz Pharma Services (India) Private Limited reported revenue of ₹185 Cr. Its focus areas include Pharmaceuticals, Distribution and Specialty Drugs.
Company details
Concordia International distributes specialty pharmaceutical drugs to healthcare providers through providing healthcare solutions, producing pharmaceutical products, distribution, and specialty drugs. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
- Headquarters Oakville, Canada
- Employees 264
- Founders Mark Thompson
- SectorsHealthcare
- Website concordiarxinternational.com
- Social X
- Legal Name Advanz Pharma Services (India) Private Limited
- Date of Incorporation 18 Jun, 1999
- Jurisdiction Mumbai, Maharashtra, India
- Indian entity revenue₹185 Cr
FY 2025 · +14% YoY
- Indian entity net profit₹21.80 Cr
FY 2025 · 12% margin
- Indian entity EBITDA₹36.90 Cr
FY 2025 · 20% margin
- Employee Count264
- Investments & Acquisitions
Associated legal entities of Concordia International
Concordia International operates through Advanz Pharma Services (India) Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Advanz Pharma Services (India) Private Limited CIN U74990MH1999FTC120396 | Active | 18 Jun 1999 | Mumbai, Maharashtra | ₹185 Cr | 264 | 3 | View details |
Board of directors of Advanz Pharma Services (India) Private Limited (Concordia International)
Advanz Pharma Services (India) Private Limited is the primary company behind Concordia International. The board of Advanz Pharma Services (India) Private Limited currently have 3 directors; the longest-serving is Bhavesh Harji Godhania, appointed in 2013. 18 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Bhavesh Harji Godhania DIN 06691706 | Director | 30 Sep 2013 | 13 yrs 1 mo | Advanz Pharma Services (India) Private Limited |
| Abhishek Sinha DIN 09512268 | Director | 23 Feb 2022 | 4 yrs 8 mo | Advanz Pharma Services (India) Private Limited |
| Gaurav Wadhwa DIN 09541267 | Director | 22 Mar 2022 | 4 yrs 7 mo | Advanz Pharma Services (India) Private Limited |
People of Concordia International
1 people are tracked at Concordia International (1 in leadership); the tracked headcount is 264.
| Name | Role | Group |
|---|---|---|
Mark Thompson | Founder, CEO | Leadership |
Complete people profiles for Concordia International
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Concordia International
Figures of Advanz Pharma Services (India) Private Limited, the primary company behind Concordia International, for FY 2025. Revenue was ₹185 Cr (+14% year on year). Net profit was ₹21.80 Cr (12% margin). EBITDA was ₹36.90 Cr (20% margin). Revenue has grown at a compounded annual rate of +18% over three years and +12% over five years.
- ₹185 CrRevenue · FY 2025 · +14% YoY
- ₹21.80 CrNet profit · 12% margin
- ₹36.90 CrEBITDA · 20% margin
- ₹1.00 CrPaid-up capital
- 264Employees (provident fund records)
- +18%Revenue CAGR, 3 years
- +12%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Advanz Pharma Services (India) Private Limited are on its company page.
Detailed financial statements for Concordia International
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Concordia International
Concordia International has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Amdipharm Mercury.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
A diversified portfolio of off-patent drugs is provided. | amcolimited.com | London, United Kingdom | 2013 | Sep 2015 | $3.5B |
Complete acquisition details for Concordia International
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Concordia International
2 dated milestones of Concordia International across 1 years, from founding to its latest funding, stage changes and deals.
- Acquisition Acquires Amdipharm Mercury.
- Founded Concordia International is founded.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Concordia International
Concordia International was founded in 2016.
Concordia International is headquartered in Oakville, Canada. It is registered at Oakville, Ontario, Canada.
Mark Thompson is the CEO of Concordia International, as recorded in our data. They have also founded this company.
Concordia International has 264 employees.
The primary company behind Concordia International, Advanz Pharma Services (India) Private Limited, reported revenue of ₹185 Cr for FY 2025, up 14% year on year.
Concordia International distributes specialty pharmaceutical drugs to healthcare providers through providing healthcare solutions, producing pharmaceutical products, distribution, and specialty drugs. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
Concordia International has made 1 acquisition, including Amdipharm Mercury.
Concordia International operates through Advanz Pharma Services (India) Private Limited.
The legal entities of Concordia International currently have 3 directors, including Bhavesh Harji Godhania, Gaurav Wadhwa, Abhishek Sinha.